Study # XL092-035_ STELLAR-305

A Phase II/III, Randomized, Double-Blind, Controlled Study of Zanzalintinib (Xl092) in Combination with Pembrolizumab Vs Pembrolizumab in The First-Line Treatment of subjects with PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Study Status:

Enrolling

Treatment Agent:

Zanzalintinib, Pembrolizumab

Description

Short Title: XL092-035/Stellar 305

This is a multicenter, randomized, double-blind, controlled Phase 2/3 trial of zanzalintinib in combination with pembrolizumab versus zanzalintinib-matched placebo in combination with pembrolizumab in subjects with PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) incurable by local therapies who have not received prior systemic therapy for recurrent or metastatic disease.

Resources and Links

National Clinical Trial Identified Number: NCT06082167

Information and next steps

Disease:

  • Head and Neck Squamous Cell Carcinoma

Study Phase:

Phase II/III

Physician Name:

Department:

Ask a Question